Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart

Area of Science:

• Oncology
• Cardiology
• Molecular Biology

Background:

• The HER2-PI3K pathway is frequently mutated in cancer, with targeted therapies approved or in clinical trials.
• This pathway is crucial for normal heart function, particularly under stress.
• Cancer therapies targeting HER2 and PI3K can lead to significant cardiac dysfunction.

Purpose of the Study:

• To review the dual role of the HER2-PI3K pathway in cancer and cardiac physiology.
• To discuss the mechanisms behind therapy-induced cardiotoxicity.
• To explore strategies for mitigating cardiac side effects of pathway inhibition.

Main Methods:

• Review of clinical trial data on HER2-targeted therapies and cardiotoxicity.
• Analysis of findings from transgenic mouse models investigating pathway kinase roles in cardiac function.
• Synthesis of research on PI3K isoform-specific effects in cardiac disease.

Main Results:

• Concurrent doxorubicin and Trastuzumab treatment significantly increases heart failure risk.
• Key kinases (PI3Kα, PDK1, Akt, mTOR) protect the heart from stress-induced dysfunction.
• PI3Kγ inhibition may improve cardiac function in failing hearts, contrasting with some transgenic model outcomes.

Conclusions:

• Inhibition of the HER2-PI3K pathway presents a therapeutic dilemma due to its dual role in cancer and heart.
• Understanding isoform-specific functions is critical for developing safer cancer treatments.
• Further research is needed to balance anti-cancer efficacy with cardiovascular safety.